Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL: Lucentis in DME
NCT03495765Phase 3Completed
- Sponsor
- Marsden Eye Specialists
- Start
- Mar 2011
- Primary completion
- Jan 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Marsden Eye Specialists. Primary endpoint: Best-Corrected Visual Acuity at 12 months. Started Mar 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03495765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03495765.